Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Prudential PLC

Prudential PLC decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 16.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,368 shares of the medical equipment provider’s stock after selling 3,848 shares during the quarter. Prudential PLC’s holdings in Lantheus were worth $1,201,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. FMR LLC increased its position in Lantheus by 198.2% during the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after purchasing an additional 1,426,465 shares during the last quarter. Norges Bank acquired a new stake in shares of Lantheus during the 4th quarter worth $29,956,000. Reinhart Partners LLC. raised its position in shares of Lantheus by 50.4% in the 4th quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock worth $84,089,000 after buying an additional 454,753 shares during the period. Rhenman & Partners Asset Management AB boosted its holdings in Lantheus by 439.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 538,986 shares of the medical equipment provider’s stock valued at $37,449,000 after acquiring an additional 438,986 shares during the last quarter. Finally, Fiera Capital Corp purchased a new stake in Lantheus during the third quarter valued at about $30,077,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LNTH shares. Truist Financial lifted their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. B. Riley lifted their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. Mizuho increased their price objective on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.17.

Get Our Latest Stock Report on LNTH

Insider Buying and Selling at Lantheus

In other news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now owns 80,244 shares of the company’s stock, valued at $6,408,285.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Heinz Christoph Maeusli sold 18,373 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the transaction, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel Niedzwiecki sold 12,873 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold 31,928 shares of company stock worth $2,530,098 in the last ninety days. 2.10% of the stock is owned by insiders.

Lantheus Trading Down 0.8 %

NASDAQ:LNTH opened at $79.28 on Tuesday. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 12.10 and a beta of 0.56. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $94.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The business’s 50-day simple moving average is $71.87 and its 200 day simple moving average is $65.12.

Lantheus (NASDAQ:LNTHGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The company had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current fiscal year.

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.